Search





Search





Markets
/
Stocks
/
nasdaq-scnx
/

Scienture Holdings Inc

SCNX

Add to Watchlist

0.403USD

-0.008-1.95%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

16.37MMarket Cap

LossP/E TTM



Scienture Holdings Inc

0.403

-0.008-1.95%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Scienture Holdings Inc

Currency: USD Updated: 2026-05-15

Key Insights

Scienture Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 107 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Scienture Holdings Inc's Score

Industry at a Glance

Industry Ranking

107 / 155

Overall Ranking

331 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Scienture Holdings Inc Highlights

StrengthsRisks

Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Growing

The company is in a growing phase, with the latest annual income totaling USD 431.61K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 431.61K.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -0.16, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 2.00M shares, increasing 12.65% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.90.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

1.500

Target Price

+264.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Scienture Holdings Inc is 6.96, ranking 127 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 56.33K, representing a year-over-year increase of 449.08%, while its net profit experienced a year-over-year increase of 11.04%.

Score

Industry at a Glance

Previous score

6.96

Change



Financials

6.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.10

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.48

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Scienture Holdings Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Scienture Holdings Inc is 6.46, ranking 120 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -0.16, which is -1590.34% below the recent high of 2.44 and -3956.97% above the recent low of -6.64.

Score

Industry at a Glance

Previous score

6.46

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 107/155

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Scienture Holdings Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

1.500

Target Price

+264.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Scienture Holdings Inc

SCNX

Apple Inc

AAPL

Ge Vernova Inc

GEV

Tapestry Inc

TPR

Verisk Analytics Inc

VRSK

Avantor Inc

AVTR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Scienture Holdings Inc is 3.33, ranking 150 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.46 and the support level at 0.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.37

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.003

Buy

RSI(14)

51.861

Neutral

STOCH(KDJ)(9,3,3)

27.563

Neutral

ATR(14)

0.032

High Vlolatility

CCI(14)

80.323

Neutral

Williams %R

63.870

Sell

TRIX(12,20)

0.268

Sell

StochRSI(14)

25.837

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

0.405

Sell

MA10

0.402

Buy

MA20

0.401

Buy

MA50

0.398

Buy

MA100

0.437

Sell

MA200

0.689

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Scienture Holdings Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 4.93%, representing a quarter-over-quarter increase of 73.38%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Narasimhan (Mani)

1.55M

+47.62%

Hariharan (Shankar Ph.D.)

3.89M

+14.75%

Mani (Narasimhan)

2.45M

+72.77%

Fell (Donald G.)

326.86K

+829.56%

Geode Capital Management, L.L.C.

316.20K

+264.27%

Jayanthi (Subbarao)

199.87K

Scoggin Management LP

150.00K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Scienture Holdings Inc is 1.04, ranking 152 out of 155 in the Pharmaceuticals industry. The company's beta value is 3.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.